Gordon A. Francis

Learn More
The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult.
The EVIDENCE trial demonstrated that interferon (IFN) beta-1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif), was significantly more effective than IFN beta-1a, 30 mcg intramuscularly(More)
BACKGROUND Fingolimod 0·5 mg once daily is approved for treatment of relapsing multiple sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in(More)